CD68/macrosialin: Not just a histochemical marker

Laboratory Investigation

Volumn 97, Issue 1, 2017, Pages 4-13

  Chistiakov, Dimitry A ^a   Killingsworth, Murry C ^b,c,d   Myasoedova, Veronika A ^e,f   Orekhov, Alexander N ^e,g,h   Bobryshev, Yuri V ^c,d,e  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF WESTERN SYDNEY   (Australia)

^e INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^f CENTRO CARDIOLOGICO MONZINO   (Italy)

^g Institute for Atherosclerosis Research   (Russian Federation)

^h MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CHLORDANE; GLYCOSYLATED PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MACROSIALIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHATIDYLSERINE; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CD68 ANTIGEN, HUMAN; CD68 PROTEIN, MOUSE; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; LOW DENSITY LIPOPROTEIN; MEMBRANE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN BINDING;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; FOAM CELL; GLYCOSYLATION; HUMAN; IMMUNITY; INFLAMMATION; NEOPLASM; NONHUMAN; OSTEOCLAST; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN STRUCTURE; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CHEMISTRY; GENETICS; IMMUNOHISTOCHEMISTRY; LYSOSOME; MACROPHAGE; METABOLISM; MOLECULAR MODEL; MOUSE; PATHOLOGY; PROGNOSIS; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BINDING SITES; BIOMARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPOPROTEINS, LDL; LYSOSOMES; MACROPHAGES; MEMBRANE PROTEINS; MICE; MODELS, MOLECULAR; NEOPLASMS; PROGNOSIS; PROTEIN BINDING; PROTEIN DOMAINS;

EID: 85008388668     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2016.116     Document Type: Article

References (90)

1. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993;81:1607-1613.
2. Holness CL, da Silva RP, Fawcett J, et al. Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/ lgp family. J Biol Chem 1993;268:9661-9666.
3. Fukuda M. Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking. J Biol Chem 1991;266: 21327-21330.
4. Winchester BG. Lysosomal membrane proteins. Eur J Paediatr Neurol 2001;5(Suppl A):11-19.
5. Yogalingam G, Bonten EJ, van de Vlekkert D, et al. Neuraminidase 1 is a negative regulator of lysosomal exocytosis. Dev Cell 2008;15:74-86.
6. Demirel Ö, Jan I, Wolters D, et al. The lysosomal polypeptide transporter TAPL is stabilized by interaction with LAMP-1 and LAMP-2. J Cell Sci 2012;125(Pt 18):4230-4240.
7. Eskelinen EL, Schmidt CK, Neu S, et al. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. Mol Biol Cell 2004;15:3132-3145.
8. Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000;406:906-910.
9. Barois N, de Saint-Vis B, Lebecque S, et al. MHC class II compartments in human dendritic cells undergo profound structural changes upon activation. Traffic 2002;3:894-905.
10. Kurushima H, Ramprasad M, Kondratenko N, et al. Surface expression and rapid internalization of macrosialin (mouse CD68) on elicited mouse peritoneal macrophages. J Leukoc Biol 2000;67:104-108.
11. van der Kooij MA, von der Mark EM, Kruijt JK, et al. Human monocyte-derived macrophages express an approximately 120-kD Ox-LDL binding protein with strong identity to CD68. Arterioscler Thromb Vasc Biol 1997;17:3107-3116.
12. Ramprasad MP, Terpstra V, Kondratenko N, et al. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci USA 1996;93:14833-14838.
13. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:2311-2316.
14. Betjes MG, Haks MC, Tuk CW, et al. Monoclonal antibody EBM11 (anti-CD68) discriminates between dendritic cells and macrophages after short-term culture. Immunobiology 1991;183:79-87.
15. Gottfried E, Kunz-Schughart LA, Weber A, et al. Expression of CD68 in non-myeloid cell types. Scand J Immunol 2008;67:453-463.
16. Jiang Z, Shih DM, Xia YR, et al. Structure, organization, and chromosomal mapping of the gene encoding macrosialin, a macrophage-restricted protein. Genomics 1998;50:199-205.
17. Greaves DR, Quinn CM, Seldin MF, et al. Functional comparison of the murine macrosialin and human CD68 promoters in macrophage and nonmacrophage cell lines. Genomics 1998;54:165-168.
18. Greaves DR, Gordon S. Macrophage-specific gene expression: current paradigms and future challenges. Int J Hematol 2002;76:6-15.
19. Kondo M. Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors. Immunol Rev 2010;238:37-46.
20. Strobl H, Scheinecker C, Riedl E, et al. Identification of CD68+lin-peripheral blood cells with dendritic precursor characteristics. J Immunol 1998;161:740-748.
21. Iqbal AJ, McNeill E, Kapellos TS, et al. Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo. Blood 2014;124:e33-e44.
22. Li AC, Guidez FR, Collier JG, et al. The macrosialin promoter directs high levels of transcriptional activity in macrophages dependent on combinatorial interactions between PU.1 and c-Jun. J Biol Chem 1998;273:5389-5399.
23. O'Reilly D, Quinn CM, El-Shanawany T, et al. Multiple Ets factors and interferon regulatory factor-4 modulate CD68 expression in a cell type-specific manner. J Biol Chem 2003;278:21909-21919.
24. Günthner R, Anders HJ. Interferon-regulatory factors determine macrophage phenotype polarization. Mediators Inflamm 2013;2013: 731023.
25. Amanzada A, Malik IA, Blaschke M, et al. Identification of CD68(+) neutrophil granulocytes in in vitro model of acute inflammation and inflammatory bowel disease. Int J Clin Exp Pathol 2013;6:561-570.
26. O'Reilly D, Greaves DR. Cell-type-specific expression of the human CD68 gene is associated with changes in Pol II phosphorylation and short-range intrachromosomal gene looping. Genomics 2007;90: 407-415.
27. La Rocca G, Anzalone R, Farina F. The expression of CD68 in human umbilical cord mesenchymal stem cells: new evidences of presence in non-myeloid cell types. Scand J Immunol 2009;70:161-162.
28. Andreeva ER, Pugach IM, Orekhov AN. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. Atherosclerosis 1997;135:19-27.
29. Carlsson SR, Fukuda M. Structure of human lysosomal membrane glycoprotein 1. Assignment of disulfide bonds and visualization of its domain arrangement. J Biol Chem 1989;264:20526-20531.
30. Arterburn LM, Earles BJ, August JT. The disulfide structure of mouse lysosome-associated membrane protein 1. J Biol Chem 1990;265: 7419-7423.
31. de Saint-Vis B, Vincent J, Vandenabeele S, et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998;9:325-336.
32. Villadangos JA, Schnorrer P, Wilson NS. Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol Rev 2005;207:191-205.
33. Wilke S, Krausze J, Büssow K. Crystal structure of the conserved domain of the DC lysosomal associated membrane protein: implications for the lysosomal glycocalyx. BMC Biol 2012;10:62.
34. Hunziker W, Geuze HJ. Intracellular trafficking of lysosomal membrane proteins. Bioessays 1996;18:379-389.
35. Fukuda M. Leukosialin, a major O-glycan-containing sialoglycoprotein defining leukocyte differentiation and malignancy. Glycobiology 1991;1:347-356.
36. Rabinowitz SS, Gordon S. Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli. J Exp Med 1991;174:827-836.
37. Rabinowitz S, Gordon S. Differential expression of membrane sialoglycoproteins in exudate and resident mouse peritoneal macrophages. J Cell Sci 1989;93(Pt 4):623-630.
38. da Silva RP, Gordon S. Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68), a macrophage-specific endosomal protein. Biochem J 1999;338(Pt 3):687-694.
39. Böhm S, Schwab I, Lux A, et al. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 2012;34: 443-453.
40. Quast I, Lünemann JD. Fc glycan-modulated immunoglobulin G effector functions. J Clin Immunol 2014;34(Suppl 1):S51-S55.
41. Rudd PM, Wormald MR, Stanfield RL, et al. Roles for glycosylation of cell surface receptors involved in cellular immune recognition. J Mol Biol 1999;293:351-366.
42. Nabi IR, Dennis JW. The extent of polylactosamine glycosylation of MDCK LAMP-2 is determined by its Golgi residence time. Glycobiology 1998;8:947-953.
43. Kundra R, Kornfeld S. Asparagine-linked oligosaccharides protect Lamp-1 and Lamp-2 from intracellular proteolysis. J Biol Chem 1999;274:31039-31046.
44. Cohnen A, Chiang SC, Stojanovic A, et al. Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood 2013;122:1411-1418.
45. Penberthy KK, Ravichandran KS. Apoptotic cell recognition receptors and scavenger receptors. Immunol Rev 2016;269:44-59.
46. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006;26: 1702-1711.
47. Ottnad E, Parthasarathy S, Sambrano GR, et al. A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: partial purification and role in recognition of oxidatively damaged cells. Proc Natl Acad Sci USA 1995;92:1391-1395.
48. Sambrano GR, Steinberg D. Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphati-dylserine. Proc Natl Acad Sci USA 1995;92:1396-1400.
49. Yoshida H, Quehenberger O, Kondratenko N, et al. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol 1998;18:794-802.
50. Tsukamoto K, Kinoshita M, Kojima K, et al. Synergically increased expression of CD36, CLA-1 and CD68, but not of SR-A and LOX-1, with the progression to foam cells from macrophages. J Atheroscler Thromb 2002;9:57-64.
51. Yamanouchi J, Takatori A, Itagaki S, et al. APA hamster model for diabetic atherosclerosis. 2. Analysis of lipids and lipoproteins. Exp Anim 2000;49:267-274.
52. Yamanouchi J, Takatori A, Nishida E, et al. Expression of lipoprotein receptors in the aortic walls of diabetic APA hamsters. Exp Anim 2002;51:33-41.
53. de Beer MC, Zhao Z, Webb NR, et al. Lack of a direct role for macrosialin in oxidized LDL metabolism. J Lipid Res 2003;44:674-685.
54. Song L, Lee C, Schindler C. Deletion of the murine scavenger receptor CD68. J Lipid Res 2011;52:1542-1550.
55. Ferenbach D, Hughes J. Macrophages and dendritic cells: what is the difference? Kidney Int 2008;74:5-7.
56. Brooks E, Simmons-Arnold L, Naud S, et al. Multinucleated giant cells' incidence, immune markers, and significance: a study of 172 cases of papillary thyroid carcinoma. Head Neck Pathol 2009;3:95-99.
57. Barros MHM, Hauck F, Dreyer JH, et al. Macrophage polarization: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One 2013;8:1-11.
58. Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 2006;37:208-222.
59. Bobryshev YV, Shchelkunova TA, Morozov IA, et al. Changes of lysosomes in the earliest stages of the development of atherosclerosis. J Cell Mol Med 2013;17:626-635.
60. Bobryshev YV. Dendritic cells and their role in atherogenesis. Lab Invest 2010;90:970-984.
61. Papageorgiou IE, Lewen A, Galow LV, et al. TLR4-activated microglia require IFN-γ to induce severe neuronal dysfunction and death in situ. Proc Natl Acad Sci USA 2016;113:212-217.
62. Cha SJ, Park K, Srinivasan P, et al. CD68 acts as a major gateway for malaria sporozoite liver infection. J Exp Med 2015;212: 1391-1403.
63. Huynh KK, Eskelinen EL, Scott CC, et al. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J 2007;26:313-324.
64. Peden AA, Oorschot V, Hesser BA, et al. Localization of the AP-3 adaptor complex defines a novel endosomal exit site for lysosomal membrane proteins. J Cell Biol 2004;164:1065-1076.
65. Chow A, Toomre D, Garrett W, et al. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 2002;418:988-994.
66. Lin XP, Almqvist N, Telemo E. Human small intestinal epithelial cells constitutively express the key elements for antigen processing and the production of exosomes. Blood Cells Mol Dis 2005;35:122-128.
67. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289: 1504-1508.
68. Ashley JW, Shi Z, Zhao H, et al. Genetic ablation of CD68 results in mice with increased bone and dysfunctional osteoclasts. PLoS One 2011;6: e25838.
69. Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol 2011;714:141-150.
70. Steinert G, Schölch S, Niemietz T, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 2014;74:1694-1704.
71. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011;52: 1913-1919.
72. Shabo I, Olsson H, Stål O, et al. Breast cancer expression of DAP12 is associated with skeletal and liver metastases and poor survival. Clin Breast Cancer 2013;13:371-377.
73. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277-286.
74. Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25:315-322.
75. Kitamura T, BZ1 Qian, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015;15:73-86.
76. Prosniak M, Harshyne LA, Andrews DW, et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res 2013;19:3776-3786.
77. Nguyen N, Bellile E, Thomas D, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck 2016;38:1074-1084.
78. Kim JH, Oh SH, Kim EJ, et al. The role of myofibroblasts in upregulation of S100A8 and S100A9 and the differentiation of myeloid cells in the colorectal cancer microenvironment. Biochem Biophys Res Commun 2012;423:60-66.
79. Mazur G, Haloń A, Wróbel T, et al. Macrophage/histiocytic antigen CD68 expression in neoplastic and reactive lymph nodes. Rocz Akad Med Bialymst 2004;49(Suppl 1):73-75.
80. Strojnik T, Kavalar R, Zajc I, et al. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res 2009;29:3269-3279.
81. Ni YH, Ding L, Huang XF, et al. Microlocalization of CD68+ tumor-associated macrophages in tumor stroma correlated with poor clinical outcomes in oral squamous cell carcinoma patients. Tumour Biol 2015;36:5291-5298.
82. Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301-308.
83. Kong LQ, Zhu XD, Xu HX, et al. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One 2013;8:e59771.
84. + cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol 2014;32:791-797.
85. Coiffier B, Li W, Henitz ED, et al. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. Clin Cancer Res 2013;19:2551-2561.
86. Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica 2011;96:186-189.
87. Agostinelli C, Gallamini A, Rigacci L, et al. The prognostic value of biologic markers in classical Hodgkin lymphoma (cHL) patients. Ann Oncol 2011;22:153-154.
88. Azambuja D, Natkunam Y, Biasoli I, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012;23:736-742.
89. Harris JA, Jain S, Ren Q, et al. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 2012;7:12.
90. Klein JL, Nguyen TT, Bien-Willner GA, et al. CD163 immunohistochem-istry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol 2014;141:381-387.